Vanitha Sekar

TL;DR: Reports from resource-limited countries suggest that initial ART programmes are as effective as in resource-rich countries, which should limit HIV drug resistance if programme effectiveness continues during scale-up.

TL;DR: Once-daily darunavir/ritonavir was both statistically noninferior and superior in virologic response to LPV/r, with a more favorable gastrointestinal and lipid profile, confirming DRV/ r as an effective, well tolerated, and durable option for antiretroviral-naive patients.

TL;DR: The results of this phase IIa proof-of-concept trial provide evidence that TMC435 has a spectrum of activity against multiple HCV genotypes, except for genotype 3.

TL;DR: No clinically relevant changes in DRV pharmacokinetics were observed when combined with TMC125; therefore DRV dose adjustment is not required; therefore TMC 125 efficacy is demonstrated and no dose adjustment of T MC125 is needed when Combined with DRV/r.

TL;DR: Darunavir/rtv should be administered with food, but exposure to darunavIR is not affected by the type of meal, as no significant differences in dar unavir plasma concentrations were observed between different fed states.